Explore

Trendline Trendline
Biokin Pharma's Iza-bren Achieves Positive Phase 3 Results in Lung Cancer Trial, Bolstering Bristol Myers Squibb Partnership

Biokin Pharma's Iza-bren Achieves Positive Phase 3 Results in Lung Cancer Trial, Bolstering Bristol Myers Squibb Partnership

Biokin Pharma's Iza-bren Achieves Positive Phase 3 Results in Lung Cancer Trial, Bolstering Bristol Myers Squibb Partnership
Trendline Trendline
Taysha Gene Therapies Reports Positive Clinical Trial Results for Rett Syndrome Treatment TSHA-102

Taysha Gene Therapies Reports Positive Clinical Trial Results for Rett Syndrome Treatment TSHA-102

Taysha Gene Therapies Reports Positive Clinical Trial Results for Rett Syndrome Treatment TSHA-102
Trendline Trendline
Merck and Moderna Announce Positive Phase 3 Trial Results for Melanoma Treatment

Merck and Moderna Announce Positive Phase 3 Trial Results for Melanoma Treatment

Merck and Moderna Announce Positive Phase 3 Trial Results for Melanoma Treatment
Rapid Read Rapid Read
Longeveron Secures $1 Million XPRIZE Healthspan Milestone Award for Stem Cell Therapy

Longeveron Secures $1 Million XPRIZE Healthspan Milestone Award for Stem Cell Therapy

Longeveron, a Miami-based regenerative medicine company, has been awarded a $1 million Milestone 2 award in the $101 million XPRIZE Healthspan competition. This recognition stems from their clinical trial data demonstrating that their lead candidate, laromestrocel, an allogeneic mesenchymal stem cell (MSC) therapy, increased the six-minute walk distance in patients with aging-related frailty. Laromestrocel is derived from the bone marrow of young, healthy adult donors and is designed for broad, one-time intervention, working through anti-inflammatory, pro-vascular, and pro-regenerative effects. The XPRIZE Healthspan competition aims to develop and test therapies that can restore muscle, cognition, and immune function lost to aging by at least ten years within a year or less of treatment. Longeveron was one of ten teams selected from over 600 international entries to advance to this milestone.
Trendline Trendline
HotSpot Therapeutics Appoints Dr. Niti Goel as Chief Medical Officer to Advance Autoimmune Disease Programs

HotSpot Therapeutics Appoints Dr. Niti Goel as Chief Medical Officer to Advance Autoimmune Disease Programs

HotSpot Therapeutics Appoints Dr. Niti Goel as Chief Medical Officer to Advance Autoimmune Disease Programs
Rapid Read Rapid Read
Merck and Moderna Announce Positive Late-Stage Trial Results for mRNA Cancer Vaccine in Melanoma

Merck and Moderna Announce Positive Late-Stage Trial Results for mRNA Cancer Vaccine in Melanoma

Merck and Moderna have announced successful late-stage clinical trial results for their personalized mRNA cancer vaccine, intismeran, when combined with Merck’s Keytruda. The trial focused on adjuvant melanoma, where patients had their disease surgically removed. The drugmakers reported that the combination treatment significantly slowed the recurrence of melanoma and its spread to other parts of the body. This marks the first randomized Phase 3 clinical trial to definitively prove the benefit of neoantigen vaccines in cancer treatment. While detailed data has not yet been released, the preliminary findings suggest a promising new approach in oncology. The vaccine utilizes mRNA technology, which has also been instrumental in developing traditional vaccines and therapeutics.
Rapid Read Rapid Read
New Research Explores Noninvasive Nasal Drug Delivery to the Brain

New Research Explores Noninvasive Nasal Drug Delivery to the Brain

A recent study published in Experimental & Molecular Medicine has analyzed various scientific breakthroughs concerning the noninvasive delivery of drugs to the brain via nasal routes. The research highlights the significant challenge posed by the blood-brain barrier (BBB), a protective layer that prevents harmful substances from entering the brain but also obstructs therapeutic drugs. While the nose offers a fast, needle-free pathway that bypasses the BBB and avoids initial drug breakdown in the liver, its efficiency in clearing foreign substances limits drug absorption time. The study identifies three advanced delivery strategies that could protect drug molecules during their journey through the nose: nanoparticles, extracellular vesicles, and living systems like genetically engineered cells, viruses, and bacteria. These systems aim to overcome the anatomical limitations of human nasal passages, which have a much smaller olfactory epithelium compared to rodents, making direct drug delivery less effective....
Rapid Read Rapid Read
Patients and Researchers Challenge FDA-Approved Cancer Drug Dosages Amidst Financial Strain and Side Effects

Patients and Researchers Challenge FDA-Approved Cancer Drug Dosages Amidst Financial Strain and Side Effects

Patients, researchers, and some medical professionals are increasingly questioning the standard dosages and durations of FDA-approved cancer drugs, citing severe side effects and significant financial burdens. Northwestern University economist Chuck Manski, for instance, opted to discontinue his nivolumab treatment early due to debilitating side effects, despite FDA protocols recommending a full year. His decision aligns with practices in countries like Canada, Israel, and Sweden, where lower doses or shorter treatment periods of drugs like nivolumab (Opdivo) and pembrolizumab (Keytruda) are already being used. The financial strain on patients is substantial; Allegra Warfield, a cancer patient, was forced to sell her home and relocate to find affordable insurance after her coverage for Kisqali ceased, with the drug costing over $16,000 monthly. A KFF survey revealed that 43% of U.S. adults skipped medication due to cost, and a Vanderbilt study found 30% of cancer drug prescriptions went unfilled. This situ...
Rapid Read Rapid Read
Engineered Probiotic Shows Promise in Animal Trials for Type 2 Diabetes Treatment

Engineered Probiotic Shows Promise in Animal Trials for Type 2 Diabetes Treatment

Researchers from East China Normal University in Shanghai have developed a novel 'living GLP-1 drug' using engineered bacteria, which has shown safety and effectiveness in pre-clinical animal trials for type 2 diabetes. This probiotic, termed a 'glucose-sensing and functional response probiotic' (GIFT), is designed to sense and reduce glucose levels by expressing glucagon-like peptide 1 (GLP-1). GLP-1 is the hormone mimicked by existing diabetes and weight-loss medications like Ozempic and Wegovy. The key innovation of GIFT is its ability to activate only when needed, providing a therapeutic dose in response to real-time blood glucose levels. This oral-deliverable system aims to bridge the gap between organ transplantation and conventional pharmaceutical treatments, potentially mitigating the side effects associated with long-term, fixed-dose administration of GLP-1 analogous drugs.
Trendline Trendline
Cell Biotech's Duolac Probiotics Achieve Global Reach with Entry into South Africa, Securing FDA GRAS Status for Strains

Cell Biotech's Duolac Probiotics Achieve Global Reach with Entry into South Africa, Securing FDA GRAS Status for Strains

Cell Biotech's Duolac Probiotics Achieve Global Reach with Entry into South Africa, Securing FDA GRAS Status for Strains
Rapid Read Rapid Read
AstraZeneca and HUTCHMED Announce Positive Phase III Results for TAGRISSO Plus Savolitinib in Lung Cancer

AstraZeneca and HUTCHMED Announce Positive Phase III Results for TAGRISSO Plus Savolitinib in Lung Cancer

AstraZeneca and HUTCHMED have reported positive high-level results from the SAFFRON Phase III trial, demonstrating that TAGRISSO (osimertinib) combined with savolitinib significantly improved progression-free survival (PFS) and overall survival (OS) in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). This trial focused on patients whose tumors exhibited high levels of MET overexpression or amplification and had progressed after prior treatment with TAGRISSO. MET-driven resistance is a common mechanism of progression in EGFRm NSCLC patients treated with third-generation EGFR-tyrosine kinase inhibitors (TKIs), often leading to poor prognosis and a lack of effective, well-tolerated treatment options. The safety profile of the combination therapy was consistent with the known profiles of each medicine, with no new safety findings observed. These findings reinforce TAGRISSO as a foundational therapy in EGFRm lung cancer and highlight the potential of this novel ...
Rapid Read Rapid Read
FDA Draft Guidance Refines Approval Process for Individualized Genetic Therapies

FDA Draft Guidance Refines Approval Process for Individualized Genetic Therapies

The U.S. Food and Drug Administration (FDA) has released draft guidance titled 'Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause.' This guidance aims to adapt the regulatory approval process for individualized genetic interventions, particularly for rare genetic disorders affecting a small number of patients. Traditionally, each variant-specific modification would require its own investigational new drug application (IND) and extensive testing, which is economically and logistically infeasible for 'n-of-1' or 'n-of-few' patient populations. The new framework outlines five key elements for approval: a specific genetic abnormality with a clear link to disease, a therapy targeting the underlying pathology, a well-characterized natural history of the disease, confirmation of successful targeting, and demonstrated improvement in clinical outcomes. The draft guidance provides more detail on nonc...